Get the Daily Brief
Latest Biotech News
Clinical trial outcomes in rare neurology
Ultragenyx’s Phase 3 program for Angelman syndrome failed to meet both the primary and key secondary endpoints, cutting short expectations for its apazunersen (GTX-102) RNA-targeting approach. The...
Cardiovascular risk therapeutics in late-stage testing
Novartis’ pelacarsen failed in the Phase 3 HORIZON trial, missing the primary goal of reducing cardiovascular death or major events such as heart attack or stroke in patients compared with...
Oncology drug development and manufacturing tactics
AbbVie reported a Phase 3 win for its multiple myeloma bispecific etentamig (T cell engager), saying the therapy met the main endpoint by improving progression or survival versus standard...
Biopharma funding and early clinical push
Superluminal Medicines raised an oversubscribed $60 million Series B to advance its pipeline of next-generation small-molecule therapies targeting challenging GPCRs in endocrine and...
Sector funding and IPO planning
ADARx Pharmaceuticals disclosed plans for an IPO after filing with the SEC, positioning the San Diego RNA interference company to raise capital to support three drugs currently in the clinic. The...
Big pharma licensing and oncology ADC expansion
GSK agreed to acquire ex-China rights to Hutchmed’s HMPL-A830 in a deal worth up to $1.295 billion, with an initial $110 million upfront payment. The asset is an antibody-targeted therapy...
Immunotherapy and engineered T-cell access
A microfluidic manufacturing approach from researchers at The Second Qilu Hospital of Shandong University boosted CAR T cell transduction at low viral doses, aiming to shorten and streamline...
Cellular imaging and disease monitoring
Researchers proposed a diffusion MRI approach using soma and neurite density imaging (SANDI) to estimate cellular-level brain damage in living patients with Huntington’s disease. In scans of 56...
Bioinformatics infrastructure for regulated drug discovery
Ionis and affiliated programs are not the only part of the compliance picture drawing scrutiny—pharma’s operational complexity is pushing more activity into governance, contracts, and auditable...
Regulatory approvals – first-in-class rare disease
The FDA cleared Ionis Pharmaceuticals’ antisense therapy Zanvastro (zilganersen) for Alexander disease in both pediatric and adult patients, establishing the first disease-modifying treatment for...
Cardiovascular drug failure – Lp(a) target reset at Phase 3
Novartis’ pelacarsen failed to reduce cardiovascular death or emergencies such as heart attacks and stroke in the Phase 3 HORIZON trial, according to statements reported by STAT+. The...
Multiple myeloma – Phase 3 success for dual-acting T-cell engager
AbbVie reported a win in a Phase 3 multiple myeloma study for etentamig, a dual-acting bispecific antibody designed to engage T cells and target tumor cells. In the trial, etentamig met the main...
Oncology licensing and partnership – GSK buys ex-China rights for KRAS/EGFR dual payload
GSK agreed to acquire ex-China rights to Hutchmed’s HMPL-A830 under a deal reported as worth up to $1.295 billion, including a $110 million upfront payment and potential development and regulatory...
Immuno-oncology – new bispecific TCR-like antibody targets PRAME complex
Researchers in South Korea developed a new cancer-targeting bispecific TCR-like antibody that binds the PRAME complex, aiming to expand immunotherapy reach to patients whose tumor targets may not...
Cell and gene therapy – company launch and in vivo CAR T focus
Typewriter Therapeutics emerged from stealth with a $56 million Series A financing, focusing on RNA-based gene therapies and in vivo CAR T strategies for cancer, autoimmune disease, and severe...
Diagnostics and clinical trials – FDA IND clearance for mucolipidosis IV gene therapy
The ML4 Foundation announced FDA clearance of an IND for an experimental gene therapy targeting mucolipidosis type IV (ML4), enabling the first U.S. clinical trial for the ultra-rare inherited...
Biomarkers and therapeutic modulation – fecal markers for C. difficile severity
Researchers identified fecal S100 calcium-binding protein B (S100B) as a potential biomarker for assessing severity in patients with Clostridioides difficile infection. The study reported a...
Financing – US-China brain-health startup secures Series B for clinical-stage pipeline
NeuShen Therapeutics, a Shanghai-and-Boston biotech led by a transpacific executive team, raised more than $80 million in a disclosed Series B to advance three clinical-stage brain-health drug...
Deal activity and platform bets – Superluminal locks $60M Series B for first clinical study
Superluminal Medicines closed an oversubscribed $60 million Series B to drive its next-gen obesity program and initiate the first clinical study. The company described a pipeline built around...
FDA approvals for rare neurology therapies
The FDA approved Ionis Pharmaceuticals’ antisense therapy Zanvastro (zilganersen) for Alexander disease in both pediatric and adult patients, marking the first disease-modifying treatment for the...